Search results
Showing 31 to 45 of 308 results for eq-5d
Evidence-based recommendations on daridorexant (QUVIVIQ) for treating long-term insomnia in adults.
Highly specialised technology (HST) evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England.
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of ...
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.
addendum on scoping workshops (PDF) . Position statement on use of the EQ-5D-5L value set for England . Get involved To get involved,...
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our position on use of the EQ-5D-5L valuation set for England
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.